This news item was issued on 8 April 2025 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand. 

ASCIA Members please log in to view.

From April 2025, registered subcutaneous immunotherapy (SCIT) treatments (ALUSTAL® HDM and ALUSTAL® 5G) will be available in Australia. These treatments are approved by the Therapeutic Goods Administration (TGA) for children, adolescents and adults with respiratory allergies (Type I, Gell and Coombs classification) to house dust mite (HDM) and grass pollen, aged 5 years and over.

ALUSTAL® HDM and ALUSTAL® 5G will be supplied as in the past, following their listing on the ARTG in 2006, i.e. same presentation, allergen profile and recommended dosing (max. dose 8 IR):

• Each vial of ALUSTAL® contains 5 ml of a suspension of native allergenic extracts absorbed on aluminum hydroxide gel
• Initiation packs will contain 3 vials: 0.1 IR/ml, 1 IR/ml and 10 IR/ml
• Maintenance packs will contain 1 vial: 10 IR/ml

Recent approvals by the TGA to qualify updated quality and manufacturing processes have enabled the re-supply of both products as registered products, providing ready access to Australian patients as locally warehoused stock (DHL). 

In contrast to unregistered products, the supply of ALUSTAL® will not require:

• Named patient orders to overseas manufacturers or
• Physician-specific authorisation, and 6 monthly reporting of use, under the TGA Authorised Prescriber Scheme.

ALUSTAL® HDM and ALUSTAL® 5G will complement Stallergenes Greer’s range of registered sublingual allergen immunotherapy (SLIT) tablet treatments (ACTAIR® and ORALAIR®), which share a common manufacturing profile (identical source materials, allergen profiles and method of standardization) and are also approved for patients aged 5 years and over, providing options to address different patient needs:

• ALUSTAL® HDM and ALUSTAL® 5G are the only TGA approved SCIT treatments available in Australia
• ACTAIR® and ALUSTAL® HDM are the only HDM allergen immunotherapy treatments that are TGA approved for use in Australian children aged under 12 years

ALUSTAL® is prepared from freeze-dried allergen extracts adsorbed onto aluminium hydroxide gel.

ABOUT ALUSTAL®

ALUSTAL® is prepared from freeze-dried allergen extracts adsorbed onto aluminium hydroxide gel.

ALUSTAL® HDM is prepared from a 50% mixture of allergen extracts from European house dust mites (Dermatophagoides pteronyssinus) & American house dust mites (Dermatophagoides farinae).

ALUSTAL® 5G is prepared from a mixture of 5 grasses including ryegrass: Cocksfoot (Dactylis glomerata L.), Sweet vernal grass (Anthoxanthum odoratum L.), Rye grass (Lolium perenne L.), Meadow grass (Poa pratensis L.) and Timothy (Phleum pratense L.)

Please contact Stallergenes Greer www.stallergenesgreer.com/au if you have any questions.

Information about AIT is available on the ASCIA website www.allergy.org.au/hp/papers/allergen-availability